<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:56:29Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6777779" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6777779</identifier>
        <datestamp>2019-10-13</datestamp>
        <setSpec>plosone</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-id journal-id-type="pmc">plosone</journal-id>
              <journal-title-group>
                <journal-title>PLoS ONE</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1932-6203</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6777779</article-id>
              <article-id pub-id-type="pmcid">PMC6777779</article-id>
              <article-id pub-id-type="pmc-uid">6777779</article-id>
              <article-id pub-id-type="pmid">31584949</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pone.0221905</article-id>
              <article-id pub-id-type="publisher-id">PONE-D-19-12516</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Surgical and Invasive Medical Procedures</subject>
                    <subj-group>
                      <subject>Transplantation</subject>
                      <subj-group>
                        <subject>Organ Transplantation</subject>
                        <subj-group>
                          <subject>Lung Transplantation</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Surgical and Invasive Medical Procedures</subject>
                    <subj-group>
                      <subject>Respiratory System Procedures</subject>
                      <subj-group>
                        <subject>Lung Transplantation</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Developmental Biology</subject>
                    <subj-group>
                      <subject>Fibrosis</subject>
                      <subj-group>
                        <subject>Pulmonary Fibrosis</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Cell Biology</subject>
                    <subj-group>
                      <subject>Cellular Types</subject>
                      <subj-group>
                        <subject>Animal Cells</subject>
                        <subj-group>
                          <subject>Blood Cells</subject>
                          <subj-group>
                            <subject>White Blood Cells</subject>
                            <subj-group>
                              <subject>T Cells</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Cell Biology</subject>
                    <subj-group>
                      <subject>Cellular Types</subject>
                      <subj-group>
                        <subject>Animal Cells</subject>
                        <subj-group>
                          <subject>Immune Cells</subject>
                          <subj-group>
                            <subject>White Blood Cells</subject>
                            <subj-group>
                              <subject>T Cells</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune Cells</subject>
                      <subj-group>
                        <subject>White Blood Cells</subject>
                        <subj-group>
                          <subject>T Cells</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune Cells</subject>
                      <subj-group>
                        <subject>White Blood Cells</subject>
                        <subj-group>
                          <subject>T Cells</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Physiology</subject>
                    <subj-group>
                      <subject>Immune Physiology</subject>
                      <subj-group>
                        <subject>Cytokines</subject>
                        <subj-group>
                          <subject>Adipokines</subject>
                          <subj-group>
                            <subject>Adiponectin</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Physiology</subject>
                    <subj-group>
                      <subject>Immune Physiology</subject>
                      <subj-group>
                        <subject>Cytokines</subject>
                        <subj-group>
                          <subject>Adipokines</subject>
                          <subj-group>
                            <subject>Adiponectin</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune System</subject>
                      <subj-group>
                        <subject>Innate Immune System</subject>
                        <subj-group>
                          <subject>Cytokines</subject>
                          <subj-group>
                            <subject>Adipokines</subject>
                            <subj-group>
                              <subject>Adiponectin</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune System</subject>
                      <subj-group>
                        <subject>Innate Immune System</subject>
                        <subj-group>
                          <subject>Cytokines</subject>
                          <subj-group>
                            <subject>Adipokines</subject>
                            <subj-group>
                              <subject>Adiponectin</subject>
                            </subj-group>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Developmental Biology</subject>
                    <subj-group>
                      <subject>Molecular Development</subject>
                      <subj-group>
                        <subject>Cytokines</subject>
                        <subj-group>
                          <subject>Adipokines</subject>
                          <subj-group>
                            <subject>Adiponectin</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Hormones</subject>
                      <subj-group>
                        <subject>Peptide Hormones</subject>
                        <subj-group>
                          <subject>Adiponectin</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Physiology</subject>
                    <subj-group>
                      <subject>Immune Physiology</subject>
                      <subj-group>
                        <subject>Cytokines</subject>
                        <subj-group>
                          <subject>Adipokines</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Physiology</subject>
                    <subj-group>
                      <subject>Immune Physiology</subject>
                      <subj-group>
                        <subject>Cytokines</subject>
                        <subj-group>
                          <subject>Adipokines</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune System</subject>
                      <subj-group>
                        <subject>Innate Immune System</subject>
                        <subj-group>
                          <subject>Cytokines</subject>
                          <subj-group>
                            <subject>Adipokines</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Immunology</subject>
                    <subj-group>
                      <subject>Immune System</subject>
                      <subj-group>
                        <subject>Innate Immune System</subject>
                        <subj-group>
                          <subject>Cytokines</subject>
                          <subj-group>
                            <subject>Adipokines</subject>
                          </subj-group>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Developmental Biology</subject>
                    <subj-group>
                      <subject>Molecular Development</subject>
                      <subj-group>
                        <subject>Cytokines</subject>
                        <subj-group>
                          <subject>Adipokines</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Physiology</subject>
                    <subj-group>
                      <subject>Physiological Parameters</subject>
                      <subj-group>
                        <subject>Body Weight</subject>
                        <subj-group>
                          <subject>Weight Loss</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Physiology</subject>
                    <subj-group>
                      <subject>Physiological Parameters</subject>
                      <subj-group>
                        <subject>Body Weight</subject>
                        <subj-group>
                          <subject>Weight Loss</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Hormones</subject>
                      <subj-group>
                        <subject>Peptide Hormones</subject>
                        <subj-group>
                          <subject>Leptin</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Physiology</subject>
                    <subj-group>
                      <subject>Physiological Parameters</subject>
                      <subj-group>
                        <subject>Body Weight</subject>
                        <subj-group>
                          <subject>Body Mass Index</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Physiology</subject>
                    <subj-group>
                      <subject>Physiological Parameters</subject>
                      <subj-group>
                        <subject>Body Weight</subject>
                        <subj-group>
                          <subject>Body Mass Index</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Decrements of body mass index are associated with poor outcomes of idiopathic pulmonary fibrosis patients</article-title>
                <alt-title alt-title-type="running-head">BMI changes in idiopathic pulmonary fibrosis</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-4251-4988</contrib-id>
                  <name>
                    <surname>Kulkarni</surname>
                    <given-names>Tejaswini</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Formal analysis</role>
                  <role content-type="http://credit.casrai.org/">Investigation</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Writing – original draft</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Yuan</surname>
                    <given-names>Kaiyu</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tran-Nguyen</surname>
                    <given-names>Thi K.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Formal analysis</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kim</surname>
                    <given-names>Young-il</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Formal analysis</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>de Andrade</surname>
                    <given-names>Joao A.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="aff" rid="aff003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Luckhardt</surname>
                    <given-names>Tracy</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Valentine</surname>
                    <given-names>Vincent G.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kass</surname>
                    <given-names>Daniel J.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Funding acquisition</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Duncan</surname>
                    <given-names>Steven R.</given-names>
                  </name>
                  <role content-type="http://credit.casrai.org/">Conceptualization</role>
                  <role content-type="http://credit.casrai.org/">Data curation</role>
                  <role content-type="http://credit.casrai.org/">Formal analysis</role>
                  <role content-type="http://credit.casrai.org/">Funding acquisition</role>
                  <role content-type="http://credit.casrai.org/">Methodology</role>
                  <role content-type="http://credit.casrai.org/">Supervision</role>
                  <role content-type="http://credit.casrai.org/">Writing – review &amp; editing</role>
                  <xref ref-type="aff" rid="aff001">
                    <sup>1</sup>
                  </xref>
                  <xref ref-type="corresp" rid="cor001">*</xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>Department of Medicine, Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America</addr-line>
              </aff>
              <aff id="aff003">
                <label>3</label>
                <addr-line>Birmingham VA Medical Center, Birmingham, Alabama, United States of America</addr-line>
              </aff>
              <aff id="aff004">
                <label>4</label>
                <addr-line>Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>West</surname>
                    <given-names>James</given-names>
                  </name>
                  <role>Editor</role>
                  <xref ref-type="aff" rid="edit1"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>Vanderbilt University Medical Center, UNITED STATES</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>srduncan@uabmc.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>4</day>
                <month>10</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2019</year>
              </pub-date>
              <volume>14</volume>
              <issue>10</issue>
              <elocation-id>e0221905</elocation-id>
              <history>
                <date date-type="received">
                  <day>2</day>
                  <month>5</month>
                  <year>2019</year>
                </date>
                <date date-type="accepted">
                  <day>16</day>
                  <month>8</month>
                  <year>2019</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2019 Kulkarni et al</copyright-statement>
                <copyright-year>2019</copyright-year>
                <copyright-holder>Kulkarni et al</copyright-holder>
                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="pone.0221905.pdf"/>
              <abstract>
                <sec id="sec001">
                  <title>Background</title>
                  <p>The processes that result in progression of idiopathic pulmonary fibrosis (IPF) remain enigmatic. Moreover, the course of this disease can be highly variable and difficult to accurately predict. We hypothesized analyses of body mass index (BMI), a simple, routine clinical measure, may also have prognostic value in these patients, and might provide mechanistic insights. We investigated the associations of BMI changes with outcome, plasma adipokines, and adaptive immune activation among IPF patients.</p>
                </sec>
                <sec id="sec002">
                  <title>Methods</title>
                  <p>Data were analyzed in an IPF discovery cohort (n = 131) from the University of Pittsburgh, and findings confirmed in patients from the University of Alabama at Birmingham (n = 148). Plasma adipokines were measured by ELISA and T-cell phenotypes determined by flow cytometry.</p>
                </sec>
                <sec id="sec003">
                  <title>Results</title>
                  <p>Transplant-free one-year survivals in subjects with the greatest rates of BMI decrements, as percentages of initial BMI (&gt;0.68%/month), were worse than among those with more stable BMI in both discovery (HR = 1.8, 95%CI = 1.1–3.2, p = 0.038) and replication cohorts (HR = 2.5, 95%CI = 1.2–5.2, p = 0.02), when adjusted for age, baseline BMI, and pulmonary function. BMI decrements &gt;0.68%/month were also associated with greater mortality after later lung transplantations (HR = 4.6, 95%CI = 1.7–12.5, p = 0.003). Circulating leptin and adiponectin levels correlated with BMI, but neither adipokine was prognostic <italic>per se</italic>. BMI decrements were significantly associated with increased proportions of circulating end-differentiated (CD28<sup>null</sup>) CD4 T-cells (CD28%), a validated marker of repetitive T-cell activation and IPF prognoses.</p>
                </sec>
                <sec id="sec004">
                  <title>Conclusions</title>
                  <p>IPF patients with greatest BMI decrements had worse outcomes, and this effect persisted after lung transplantation. Weight loss in these patients is a harbinger of poor prognoses, and may reflect an underlying systemic process, such as adaptive immune activation.</p>
                </sec>
              </abstract>
              <funding-group>
                <award-group id="award001">
                  <funding-source>
                    <institution>National Institutes of Health</institution>
                  </funding-source>
                  <award-id>HL126990</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Kass</surname>
                      <given-names>Daniel J.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="award002">
                  <funding-source>
                    <institution>National Institutes of Health</institution>
                  </funding-source>
                  <award-id>HL119960</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Duncan</surname>
                      <given-names>Steven R.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <funding-statement>SRD received a grant from National Institutes of Health; HL119960; <ext-link ext-link-type="uri" xlink:href="https://www.nih.gov">https://www.nih.gov</ext-link>. DJK received a grant from National Institutes of Health; HL126990; <ext-link ext-link-type="uri" xlink:href="https://www.nih.gov">https://www.nih.gov</ext-link>. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="4"/>
                <table-count count="1"/>
                <page-count count="12"/>
              </counts>
              <custom-meta-group>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>All relevant data are within the paper and its Supporting Information files.</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec005">
              <title>Introduction</title>
              <p>The median survival of patients with idiopathic pulmonary fibrosis (IPF) is three-to-four years, but the courses of individuals with this lung disease are highly variable [<xref rid="pone.0221905.ref001" ref-type="bibr">1</xref>]. An accurate means to predict IPF patient outcomes could enable health care providers to better optimize the timing of lung transplantation referrals, encourage compliance with medications that have bothersome side effects among those at greatest risk, and identify particular subpopulations for experimental clinical trials or timely end-of-life counseling. Accordingly, the development of prognostic indicators for IPF is an active area of interest [<xref rid="pone.0221905.ref002" ref-type="bibr">2</xref>–<xref rid="pone.0221905.ref006" ref-type="bibr">6</xref>]. Nonetheless, currently available prognostic instruments do not have perfect accuracy or universal applicability [<xref rid="pone.0221905.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0221905.ref003" ref-type="bibr">3</xref>, <xref rid="pone.0221905.ref007" ref-type="bibr">7</xref>–<xref rid="pone.0221905.ref010" ref-type="bibr">10</xref>].</p>
              <p>Body mass index (BMI) is routinely assessed in clinic practice, and is available in any facility that can measure patient heights and weights. Associations between BMI and prognoses have been reported among patients with chronic obstructive pulmonary disease (COPD) [<xref rid="pone.0221905.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0221905.ref012" ref-type="bibr">12</xref>], and several other disorders such as rheumatoid arthritis [<xref rid="pone.0221905.ref013" ref-type="bibr">13</xref>] and heart failure [<xref rid="pone.0221905.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0221905.ref014" ref-type="bibr">14</xref>]. While recent studies have also linked BMI to survival in IPF patients [<xref rid="pone.0221905.ref015" ref-type="bibr">15</xref>–<xref rid="pone.0221905.ref018" ref-type="bibr">18</xref>], the mechanism(s) associated with weight loss in this population have not been explored. Several factors have been causally implicated in pathological BMI decrements among other disease populations such as chronic inflammation, oxidative stress, and adipose tissue metabolism [<xref rid="pone.0221905.ref019" ref-type="bibr">19</xref>–<xref rid="pone.0221905.ref021" ref-type="bibr">21</xref>].</p>
              <p>We have noted several anecdotal examples in our clinical practices wherein unexplained weight loss in patients with IPF seemed to portend poor prognoses. Consequently, we conducted analyses here to systematically test the hypothesis that dynamic changes of BMI may be associated with decreased survival among IPF patients. We postulated too that BMI reductions in this population might be related to an underlying systemic process(es) and not merely a simple, direct correlate of pulmonary physiology <italic>per se</italic>.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec006">
              <title>Materials and methods</title>
              <sec id="sec007">
                <title>Subjects</title>
                <p>Clinical information about patients with ≥2 BMI measures between May 2000 and June 2014 was abstracted from prospectively recorded research registries at the University of Pittsburgh Medical Center (UPMC) and the University of Alabama at Birmingham (UAB). All subjects fulfilled IPF consensus criteria [<xref rid="pone.0221905.ref001" ref-type="bibr">1</xref>]. The Institutional Review Boards for Human Research approved this project, including waiver of informed consent at both institutions (UAB: E150318008 and UPMC: MOD0610029-14).</p>
              </sec>
              <sec id="sec008">
                <title>Clinical variables</title>
                <p>Measurements of forced vital capacity (FVC) and diffusion capacity for carbon monoxide (D<sub>L</sub>CO), expressed as percentages of predicted values (%FVC and %D<sub>L</sub>CO, respectively), were performed per guidelines [<xref rid="pone.0221905.ref022" ref-type="bibr">22</xref>].</p>
                <p>BMI (kg/m<sup>2</sup>) was calculated as weight/height<sup>2</sup>. BMI measurements were made using medical-grade scales and were performed as routine clinical practices in dedicated interstitial lung disease clinics by trained personnel. BMIs at the subject's last clinic visit prior to their death (all-cause mortality), lung transplantation, or June 1, 2014, were denoted as BMI<sub>last</sub>. Measurements made at clinic visits closest to the one-year prior to BMI<sub>last</sub> were designated as BMI<sub>first</sub>. Percentage changes of BMI during these intervals (%BMI<sub>delta</sub>) were calculated as ([BMIlast−BMI<sub>first</sub>]/BMI<sub>first</sub>) x 100. Rates of relative changes were calculated by dividing %BMI<sub>delta</sub> by the interval (in months) during which these changes occurred (i.e., %BMI<sub>delta</sub>/month).</p>
                <p>The primary endpoint of the study was one-year transplant-free survival (TFS), defined as the interval (for up to 12 months) after BMI<sub>last</sub> that subjects were alive and had not undergone lung transplantation. Deaths from any cause or transplantations were considered uncensored events. Transplant-free survivors were censored at one-year after BMI<sub>last</sub>, as were any cases in this subpopulation that were lost to follow-up during the 12-month observation. Mortality ascertainments were made by review of clinic and hospital records, searches of internet databases (including obituary listings), and telephone interviews.</p>
                <p>To perform survival analyses, we dichotomized discovery cohort subjects into the quartile with the greatest rates of weight loss <italic>vs</italic>. the remaining 75% who had lesser BMI reductions. The cut off value distinguishing these two categories was 0.68%/month in the discovery cohort and this value was applied to similarly dichotomize subjects in the validation cohort, and those who underwent lung transplantation.</p>
              </sec>
              <sec id="sec009">
                <title>Circulating adipokines</title>
                <p>Leptin and adiponectin were measured in plasma specimens by ELISA (R&amp;D Systems, Minneapolis, MN) according to the manufacturer's instructions.</p>
              </sec>
              <sec id="sec010">
                <title>Flow cytometry</title>
                <p>Peripheral blood mononuclear cells (PBMNC) were isolated from phlebotomy specimens by density gradient centrifugation [<xref rid="pone.0221905.ref023" ref-type="bibr">23</xref>]. CD4 T-cell CD28 expression was determined by methods detailed previously [<xref rid="pone.0221905.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0221905.ref024" ref-type="bibr">24</xref>]. CD28% values were defined as the proportion of circulating CD4 T-cells that co-express CD28 [<xref rid="pone.0221905.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0221905.ref024" ref-type="bibr">24</xref>]. Downregulation of CD28 on surfaces of circulating CD4 T-cells is a specific and validated marker of repeated antigen encounters and adaptive immune activation (23,24).</p>
              </sec>
              <sec id="sec011">
                <title>Statistical analysis</title>
                <p>Descriptive statistics were presented as means ± SD and frequencies, or as proportions for categorical variables. Continuous variables were compared by Mann-Whitney. Bivariate associations were evaluated by Chi-square or Fisher’s exact tests. Intergroup differences in time-to-event were evaluated by Kaplan-Meier survival analyses and log-rank tests. Multivariable cox proportional-hazards regression analyses were used to assess TFS after accounting for age and baseline BMI as a continuous variable and absolute decline by 10 percentage points of %FVC and %D<sub>L</sub>CO, over the same interval as the measured BMI decrement, as categorical variables. These physiological variables have often been associated with survival in IPF [<xref rid="pone.0221905.ref025" ref-type="bibr">25</xref>] and hence, were included in the multivariable models evaluating associations between TFS and decrements of %BMI<sub>delta</sub> and CD28 expression. Associations between continuous variables (BMI and adiponectin levels) were established by Spearman correlations. P-values &lt;0.05 were considered significant. Statistical analyses were performed using SAS software<sup>TM</sup> (SAS 9.4).</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec012">
              <title>Results</title>
              <sec id="sec013">
                <title>Subject characteristics</title>
                <p>Characteristics of the subjects are detailed in <xref rid="pone.0221905.t001" ref-type="table">Table 1</xref>.</p>
                <table-wrap id="pone.0221905.t001" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0221905.t001</object-id>
                  <label>Table 1</label>
                  <caption>
                    <title>Demographics and baseline characteristics of subjects.</title>
                  </caption>
                  <alternatives>
                    <graphic id="pone.0221905.t001g" xlink:href="pone.0221905.t001"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th align="center" rowspan="1" colspan="1">UPMC Discovery Cohort<break/>(n = 131)</th>
                          <th align="center" rowspan="1" colspan="1">UAB Validation Cohort<break/>(n = 148)</th>
                          <th align="center" rowspan="1" colspan="1">p-value</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Age (mean, years)</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">68.9 ± 8.9</td>
                          <td align="left" rowspan="1" colspan="1">65.3 ± 8.9</td>
                          <td align="left" rowspan="1" colspan="1">&lt;0.01</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Gender (male)</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">101 (77%)</td>
                          <td align="left" rowspan="1" colspan="1">100 (68%)</td>
                          <td align="left" rowspan="1" colspan="1">0.06</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Race (white)</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">129 (99%)</td>
                          <td align="left" rowspan="1" colspan="1">138 (94%)</td>
                          <td align="left" rowspan="1" colspan="1">0.01</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>Current/Former smoker</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">96 (74%)</td>
                          <td align="left" rowspan="1" colspan="1">105 (72%)</td>
                          <td align="left" rowspan="1" colspan="1">0.07</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> <bold>BMI</bold><sub><bold>first</bold></sub>
<bold>(m</bold><sup><bold>2</bold></sup><bold>)</bold></td>
                          <td align="left" rowspan="1" colspan="1">29.8 ± 5.0</td>
                          <td align="left" rowspan="1" colspan="1">29.9 ± 6.1</td>
                          <td align="left" rowspan="1" colspan="1">0.90</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">
                            <bold>BMI Interval (months)</bold>
                          </td>
                          <td align="left" rowspan="1" colspan="1">10.6 ± 3.8</td>
                          <td align="left" rowspan="1" colspan="1">10.7 ± 4.4</td>
                          <td align="left" rowspan="1" colspan="1">0.50</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> <bold>%Predicted FVC (baseline)</bold></td>
                          <td align="left" rowspan="1" colspan="1">64 ± 17</td>
                          <td align="left" rowspan="1" colspan="1">59 ± 18</td>
                          <td align="left" rowspan="1" colspan="1">0.03</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1"> <bold>%Predicted D</bold><sub><bold>L</bold></sub><bold>CO (baseline)</bold></td>
                          <td align="left" rowspan="1" colspan="1">48 ± 17</td>
                          <td align="left" rowspan="1" colspan="1">44 ± 14</td>
                          <td align="left" rowspan="1" colspan="1">0.06</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t001fn001">
                      <p>Data represent absolute numbers, and/or means ± SD, and/or percentages. UPMC: University of Pittsburgh, UAB: University of Alabama at Birmingham, BMI: Body Mass Index; BMI Interval denotes elapsed time between BMI measures (BMI<sub>first</sub> and BMI<sub>last</sub>, respectively); FVC: Forced Vital Capacity; D<sub>L</sub>CO: Diffusing Capacity for Carbon Monoxide; Current/former smoker denotes subjects with ≥ 5 pack-years of cigarette smoking.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="sec014">
                <title>Discovery cohort</title>
                <p>Among the discovery cohort (n = 131), 38 subjects (29%) underwent transplantation, and there were 47 (36%) pre-transplant deaths. One subject was lost to follow-up 7.5 months after BMI<sub>last</sub> and was censored at that time, whereas all other participants were observed for 12 months, or until their deaths or transplantations. %BMI<sub>delta</sub>, adjusted for the interval over which the weight loss occurred (%BMI<sub>delta</sub>/month) was -0.42 ± 0.70%/month for those with transplants or deaths <italic>vs</italic>. -0.09 ± 0.44%/month among non-transplanted survivors (p&lt;0.01). TFS was significantly worse among subjects in the quartile with the greatest rates of BMI decrements (which corresponded to BMI reductions &gt;0.68%/month) compared to patients with a more stable BMI (<xref ref-type="fig" rid="pone.0221905.g001">Fig 1A</xref>). The increased risk with greater BMI decrements also persisted in the multivariate regression analysis adjusting for age, pulmonary function and initial BMI (HR = 1.8, 95%CI = 1.1–3.2, p = 0.038).</p>
                <fig id="pone.0221905.g001" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0221905.g001</object-id>
                  <label>Fig 1</label>
                  <caption>
                    <title>Transplant-free survival dichotomized by BMI decrement.</title>
                    <p><bold>A)</bold> Transplant-free survival (TFS) among the University of Pittsburgh Medical Center (UPMC) discovery cohort IPF patients was worse in the quartile with the greatest decrements of BMI rates (%BMI<sub>delta</sub>/month). The cut-off value that defined this worst performing quartile was &gt;0.68%/month. <bold>B)</bold> TFS among the University of Alabama at Birmingham (UAB) replication cohort was similarly reduced among the IPF patients with BMI decrements &gt;0.68%/month.</p>
                  </caption>
                  <graphic xlink:href="pone.0221905.g001"/>
                </fig>
                <p>In order to exclude the possibility these results might be confounded by the intentional weight loss of a few patients, in order for them to become listed for transplantation, we conducted a <italic>post hoc</italic> analyses that omitted patients with initial BMI &gt;30 (this is generally the upper limit BMI for lung transplantation eligibility). Despite now having a smaller study cohort (n = 93), the TFS among them who had the greatest BMI<sub>delta</sub> decrements (&gt;0.68%/month) was still significantly worse than those with more stable BMI (HR = 2.1, 95%CI = 1.1–3.8, p = 0.02).</p>
                <p>To further exclude the possibility of bias due to intentional weight loss, which would have been a necessary prelude to their transplantations, we also performed an analysis that excluded the patients who had lung transplantation at any time. Nonetheless, survival in the subjects with the greatest rates of BMI<sub>delta</sub> decrements remained significantly worse than those with more stable BMI (HR = 2.9, 95%CI = 1.6–5.2, p = 0.0002).</p>
                <p>Yet another <italic>post hoc</italic> analyses, in which lung transplantations were instead treated as censored events, again showed increased risk of death among those IPF patients with the greatest BMI<sub>delta</sub> decrements (HR = 2.8, 95%CI = 1.5–5.0, p = 0.003).</p>
              </sec>
              <sec id="sec015">
                <title>Validation cohort</title>
                <p>The validation cohort was fortuitously well-matched in most respects to the initial discovery subjects (<xref rid="pone.0221905.t001" ref-type="table">Table 1</xref>). Most of the differences between these two groups were comparatively small and perhaps of greater mathematical significance than biological importance.</p>
                <p>Eighty-nine (89) of the 148 validation cohort subjects (60%) subjects died prior to transplantation and 23 others (16%) had lung transplantations. All subjects in this cohort were observed for 12 months or until death or transplantation (i.e., there were no censored events). Time-adjusted rates of %BMI<sub>delta</sub> were -0.41 ± 0.84%/month <italic>vs</italic>. -0.06 ± 0.74%/month among subjects with and without adverse events, respectively (p&lt;0.01). Stratification of the replication cohort into subjects with BMI<sub>delta</sub> reductions greater than or less than the 0.68%/month cut off value found in the discovery cohort again showed subjects with more extreme weight loss had a 2-fold increased risk of a worse outcomes (<xref ref-type="fig" rid="pone.0221905.g001">Fig 1B</xref>). Multivariable adjustments for age, pulmonary function, and initial BMI did not alter the association between decrements of %BMI<sub>delta</sub> and TFS at one year in this cohort (HR = 2.5, 95%CI = 1.2–5.2, p = 0.02).</p>
              </sec>
              <sec id="sec016">
                <title>Association of BMI with Post-transplant survival</title>
                <p>We also examined effects of BMI changes on mortality after subsequent lung transplantations in the UPMC discovery subjects. The proportion of subjects who underwent lung transplantation among the UAB cohort was too small to permit meaningful survival analyses in this group.</p>
                <p>Stratification of the transplant recipients into those with pre-transplantation BMI decrements exceeding 0.68%/month <italic>vs</italic>. those with more stable BMI showed survival of the latter were significantly better (<xref ref-type="fig" rid="pone.0221905.g002">Fig 2A</xref>). Subjects with decrements of BMI<sub>delta</sub> greater than 0.68%/month in the year preceding lung transplant had more than 4-fold increased risk of death compared to those with lesser BMI<sub>delta</sub> decrements (HR = 4.6; 95%CI 1.7–12.6, p = 0.003). Deaths attributable to infections predominated in those with the greatest pre-transplant BMI<sub>delta</sub>, whereas mortality due to cancers or chronic allograft failure was increased among those with more stable BMI (<xref ref-type="fig" rid="pone.0221905.g002">Fig 2B</xref>).</p>
                <fig id="pone.0221905.g002" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0221905.g002</object-id>
                  <label>Fig 2</label>
                  <caption>
                    <title>Post-transplant mortality.</title>
                    <p><bold>A)</bold> Mortality among IPF patients with pre-transplant BMI decrements &gt;0.68%/month was increased after their transplantations. <bold>B)</bold> Causes of deaths among these transplant recipients tended to be associated with their earlier, pre-transplant BMI changes.</p>
                  </caption>
                  <graphic xlink:href="pone.0221905.g002"/>
                </fig>
              </sec>
              <sec id="sec017">
                <title>Circulating adiopokine levels</title>
                <p>Plasma samples were available from 92 UPMC patients that had been obtained at the same time as BMI<sub>first</sub> (n = 69), or BMI<sub>last</sub> (n = 64), or both BMI determinations (n = 41). Leptin concentrations correlated with corresponding BMI<sub>first</sub> (<italic>r</italic><sub><italic>s</italic></sub> = 0.7, p&lt;0.01) and BMI<sub>last</sub> (<italic>r</italic><sub><italic>s</italic></sub> = 0.5, p&lt;0.01). Longitudinal BMI changes also correlated with concomitant alterations of plasma leptin (<xref ref-type="fig" rid="pone.0221905.g003">Fig 3A</xref>). There were no associations of longitudinal change in leptin levels with TFS (HR = 1.0; 95%CI 1.0–1.02, p = 0.3).</p>
                <fig id="pone.0221905.g003" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0221905.g003</object-id>
                  <label>Fig 3</label>
                  <caption>
                    <title>Correlations of body mass index and adiponectins.</title>
                    <p><bold>A)</bold> Changes in leptin concentrations were correlated with corresponding changes of BMI during the intervals from BMI<sub>first</sub> to BMI<sub>last</sub>. <bold>B)</bold> Changes in adioponectin concentrations were inversely correlated with corresponding changes of BMI during the intervals from BMI<sub>first</sub> to BMI<sub>last</sub>.</p>
                  </caption>
                  <graphic xlink:href="pone.0221905.g003"/>
                </fig>
                <p>Cross-sectional adiponectin levels did not correlate with either BMI<sub>first</sub> (<italic>r</italic><sub><italic>s</italic></sub> = -0.12, p = 0.31) or BMI<sub>last</sub> (<italic>r</italic><sub><italic>s</italic></sub> = -0.12, p = 0.34). Longitudinal changes of adiponectin levels were modestly correlated [inversely] with corresponding BMI<sub>delta</sub> (<xref ref-type="fig" rid="pone.0221905.g003">Fig 3B</xref>). Adiponectin levels were also unrelated to concomitant leptin values at BMI<sub>first</sub> (<italic>r</italic><sub><italic>s</italic></sub> = 0.05, p = 0.69) and BMI<sub>last</sub> (<italic>r</italic><sub><italic>s</italic></sub> = -0.03, p = 0.81). There were no significant associations of longitudinal changes in adiponectin levels with TFS (HR = 1.0; 95%CI 1.0–1.02, p = 0.2).</p>
              </sec>
              <sec id="sec018">
                <title>BMI and CD4 T-cell Differentiation</title>
                <p>In order to explore possible linkages between weight loss and immune activation, as described in other populations [<xref rid="pone.0221905.ref020" ref-type="bibr">20</xref>], we analyzed CD4 T-cell CD28 expression relative to BMI determinations. CD4 T-cells were examined at BMI<sub>first</sub> in 120 discovery cohort subjects. Survival analyses confirmed low [abnormal] CD28% was associated with decreased one-year TFS compared to subjects with normal CD28% (<xref ref-type="fig" rid="pone.0221905.g004">Fig 4A</xref>) (23), which persisted after multivariable adjustment (HR = 1.8, 95%CI = 1.1–3.1, p = 0.04).</p>
                <p>CD28% were significantly reduced (more abnormal) in the IPF subjects who subsequently had the greatest BMI decrements (<xref ref-type="fig" rid="pone.0221905.g004">Fig 4B</xref>).</p>
                <fig id="pone.0221905.g004" orientation="portrait" position="float">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0221905.g004</object-id>
                  <label>Fig 4</label>
                  <caption>
                    <title>Correlation of body mass index and CD4 T-cell differentiation.</title>
                    <p><bold>A)</bold> Transplant-free survival (TFS) was worse among IPF subjects with low CD28 expression compared to subjects with high CD28%. <bold>B)</bold> The proportion of CD4 T-cells that express CD28 (CD28%) at BMI<sub>first</sub> was diminished among the quartile of IPF subjects with greatest BMI decrements.</p>
                  </caption>
                  <graphic xlink:href="pone.0221905.g004"/>
                </fig>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec019">
              <title>Discussion</title>
              <p>These data show that BMI decrements among IPF patients are associated with increased risks of transplantation and/or death. This relationship was evident in analyses of BMI changes as percentages of initial values, and with BMI changes as functions of time. Moreover, these findings were very similar in two distinct cohorts (<xref ref-type="fig" rid="pone.0221905.g001">Fig 1A and 1B</xref>) and independent of pulmonary physiological parameters that are widely used in IPF prognostic indices [<xref rid="pone.0221905.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0221905.ref003" ref-type="bibr">3</xref>], or age, or initial BMI. This study further demonstrated a potential link for adipokine dysregulation and immune activation in association with BMI decrements and poor outcomes in IPF patients. Most importantly, the present data indicate monitoring BMI may have prognostic value in IPF patients (<xref ref-type="fig" rid="pone.0221905.g001">Fig 1A and 1B</xref>). The robustness and reproducibility of the findings here in relatively large, independent study populations defined by contemporary criteria illustrate the importance of longitudinal BMI reductions as a mortality risk in IPF, even in patients who are variously under- or over-weight at their initial diagnosis.</p>
              <p>Weight loss is a harbinger of poor outcomes in several chronic conditions including COPD, rheumatoid arthritis, congestive heart failure, coronary artery disease, asthma and bronchiectasis [<xref rid="pone.0221905.ref012" ref-type="bibr">12</xref>–<xref rid="pone.0221905.ref014" ref-type="bibr">14</xref>, <xref rid="pone.0221905.ref026" ref-type="bibr">26</xref>, <xref rid="pone.0221905.ref027" ref-type="bibr">27</xref>] and has recently been reported in association with mortality in IPF [<xref rid="pone.0221905.ref015" ref-type="bibr">15</xref>–<xref rid="pone.0221905.ref018" ref-type="bibr">18</xref>]. Baseline BMI was reported to be associated with survival in a single center IPF cohort [<xref rid="pone.0221905.ref015" ref-type="bibr">15</xref>]. In contrast to that earlier report, more recent studies link longitudinal weight loss, but not baseline BMI, to survival in IPF patients [<xref rid="pone.0221905.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0221905.ref018" ref-type="bibr">18</xref>]; analogous to our findings (<xref ref-type="fig" rid="pone.0221905.g001">Fig 1A and 1B</xref>).</p>
              <p>In distinction to these reports, however, we explored additional characteristics of BMI decrements in IPF. A novel observation of the present study is the effect of pre-transplant BMI decrements on IPF mortality after lung transplantations (<xref ref-type="fig" rid="pone.0221905.g002">Fig 2A</xref>). This finding is contrary to prior suggestions of better survival in association with pre-transplant weight loss in patients with various chronic lung diseases [<xref rid="pone.0221905.ref016" ref-type="bibr">16</xref>]. However, patients in those earlier reports intentionally lost weight by voluntary dietary regulation and exercise, which is contrary to the weight loss in our IPF population which was anecdotally observed in almost all cases to be unintended. Although subject numbers are small here, the present data indicating trends between pre-transplant BMI changes and causes of later mortality (<xref ref-type="fig" rid="pone.0221905.g002">Fig 2B</xref>), also suggests weight loss may be related to (or possibly reflect) systemic processes that influence host defense.</p>
              <p>Accumulations of CD28<sup>null</sup> effector-memory T-cells are a specific consequence of repeated antigen receptor activation by conventional peptide epitopes and are not simply due to nonspecific global inflammation [<xref rid="pone.0221905.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0221905.ref024" ref-type="bibr">24</xref>, <xref rid="pone.0221905.ref028" ref-type="bibr">28</xref>]. IPF subjects with the greatest BMI decrements, and worst prognoses, had the most marked CD4 T-cell end-differentiation (<xref ref-type="fig" rid="pone.0221905.g004">Fig 4B</xref>). Although the role of immune processes in IPF has been controversial, several recent studies have shown adaptive immune activation among many of the patients afflicted with this lung disease, and in several examples these immunologic abnormalities are highly related to clinical manifestations and patient outcomes [<xref rid="pone.0221905.ref023" ref-type="bibr">23</xref>, <xref rid="pone.0221905.ref029" ref-type="bibr">29</xref>–<xref rid="pone.0221905.ref035" ref-type="bibr">35</xref>]. While cause and effect cannot be established from the present findings, these data are also consistent with findings in other populations that link adaptive immune activation and cachexia [<xref rid="pone.0221905.ref020" ref-type="bibr">20</xref>]<sup>.</sup></p>
              <p>Adipokines such as leptin and adiponectin are proteins secreted predominantly by adipocytes that can modulate body weight via their effects on metabolic regulation [<xref rid="pone.0221905.ref036" ref-type="bibr">36</xref>]. Adiponectin expression has been recently shown to be reduced in lungs of IPF patients [<xref rid="pone.0221905.ref037" ref-type="bibr">37</xref>]. Changes in circulating adipokine concentrations are adversely linked to lung function abnormalities in COPD populations [<xref rid="pone.0221905.ref038" ref-type="bibr">38</xref>, <xref rid="pone.0221905.ref039" ref-type="bibr">39</xref>] and also associated with various effects on the adaptive immune system [<xref rid="pone.0221905.ref040" ref-type="bibr">40</xref>]. While changes in leptin and adiponectin levels were correlated with BMI decrements here (<xref ref-type="fig" rid="pone.0221905.g003">Fig 3A and 3B</xref>), we did not identify significant relationships of these adipokines with survival. The regulation of these cytokines is complex, however, and is variously affected by poorly understood mechanisms, particularly in conditions of disease. As examples, leptin production is increased by acute phase reactants and other immune mediators [<xref rid="pone.0221905.ref041" ref-type="bibr">41</xref>], and circulating concentrations of this adipokine are typically higher in conditions characterized by acute or chronic inflammation [<xref rid="pone.0221905.ref042" ref-type="bibr">42</xref>]. Adiponectin levels are generally decreased in the context of the low-level chronic inflammation that is associated with obesity, but may be unchanged or even increased in other inflammatory conditions [<xref rid="pone.0221905.ref043" ref-type="bibr">43</xref>]. The lack of an overt relationship between adipokines and disease progression has also been described in several other syndromes [<xref rid="pone.0221905.ref044" ref-type="bibr">44</xref>].</p>
              <p>The present report describes our initial investigation into the association of BMI changes with outcomes among IPF patients with IPF. It is not a definitive validation of the BMI<sub>delta</sub> for clinical use, and to attempt a rigorous comparison with other prognostic indices was beyond the intent and scope of this study. Instead, this analysis was prompted by clinical observations that led us to hypothesize BMI<sub>delta</sub> reductions may be a significant, if under-appreciated, portent of poor outcomes in IPF patients. Moreover, after having found our hypothesis was plausible, incremental studies were performed to explore underlying mechanisms that might account for the BMI<sub>delta</sub> and, more importantly, possibly contribute to disease progression.</p>
              <p>This report has limitations. By necessity it is a retrospective analysis, and has the inherent flaws of these study types. Cryptic biases are possible, such as over-representations of more healthy survivors, due to premature subject drop out of the most ill patients prior to their second BMI measures. Although the aggregate subject number here is greater than in analogous reports [<xref rid="pone.0221905.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0221905.ref018" ref-type="bibr">18</xref>], the power of future investigations will be enhanced by even larger group sizes and more frequent collection of prospective, longitudinal data and biological specimens. Adipokine analyses of small populations seem particularly liable to confounding due to the complexities of their regulation. Details about dietary modifications (intended to gain or lose weight) will enhance further studies. The subjects here were analyzed prior to the introduction of anti-fibrotic medications [<xref rid="pone.0221905.ref045" ref-type="bibr">45</xref>], and it is possible those agents could have various effects on dietary intake, weight loss, and/or survival that will need consideration in future investigations. Causes of death in the non-transplanted IPF patients here were often not available, and more stringent mortality assessments in larger subject numbers could illuminate clinically-significant relationships, as seen in the lung transplant recipients (<xref ref-type="fig" rid="pone.0221905.g002">Fig 2B</xref>). Despite these limitations, however, the present findings may prompt considerations to test the incorporation of BMI<sub>delta</sub>, perhaps in addition to other demographic and physiological parameters [<xref rid="pone.0221905.ref002" ref-type="bibr">2</xref>, <xref rid="pone.0221905.ref003" ref-type="bibr">3</xref>, <xref rid="pone.0221905.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0221905.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0221905.ref008" ref-type="bibr">8</xref>–<xref rid="pone.0221905.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0221905.ref025" ref-type="bibr">25</xref>], in the future development and validation of indices that could enrich and enhance our ability to predict the course of IPF in individual patients.</p>
            </sec>
            <sec sec-type="conclusions" id="sec020">
              <title>Conclusions</title>
              <p>IPF patients with more stable BMI had longer transplant-free survival than patients with greater weight decrements in both IPF study cohorts. These findings could be an impetus for further research to more fully determine causes of the weight loss in IPF patients and better understand the pathological mechanism(s) that link BMI<sub>delta</sub> to progression and outcome of this lung disease. The present data also indicate changes of BMI <italic>per se</italic>, or in combinations with other measures, could eventually be a useful clinical tool to identify IPF patients with increased risks of near-term mortality.</p>
            </sec>
            <sec sec-type="supplementary-material" id="sec021">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="pone.0221905.s001">
                <label>S1 Data</label>
                <caption>
                  <title>Data utilized for the analysis of this study.</title>
                  <p>(XLSX)</p>
                </caption>
                <media xlink:href="pone.0221905.s001.xlsx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ref-list>
              <title>References</title>
              <ref id="pone.0221905.ref001">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>Raghu</surname><given-names>G</given-names></name>, <name><surname>Collard</surname><given-names>HR</given-names></name>, <name><surname>Egan</surname><given-names>JJ</given-names></name>, <name><surname>Martinez</surname><given-names>FJ</given-names></name>, <name><surname>Behr</surname><given-names>J</given-names></name>, <name><surname>Brown</surname><given-names>KK</given-names></name>, <etal>et al</etal><article-title>An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management</article-title>. <source>American journal of respiratory and critical care medicine</source>. <year>2011</year>;<volume>183</volume>(<issue>6</issue>):<fpage>788</fpage>–<lpage>824</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.2009-040GL</pub-id> .<?supplied-pmid 21471066?><pub-id pub-id-type="pmid">21471066</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>Puxeddu</surname><given-names>E RP</given-names></name>. <article-title>Prognostic scoring systems for clinical course and survival in idiopathic pulmonary fibrosis</article-title>. <source>World J Respirol</source>. <year>2016</year>;<volume>6</volume>(<issue>1</issue>):<fpage>14</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.5320/wjr.v6.i1.14</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Robbie</surname><given-names>H</given-names></name>, <name><surname>Daccord</surname><given-names>C</given-names></name>, <name><surname>Chua</surname><given-names>F</given-names></name>, <name><surname>Devaraj</surname><given-names>A</given-names></name>. <article-title>Evaluating disease severity in idiopathic pulmonary fibrosis</article-title>. <source>Eur Respir Rev</source>. <year>2017</year>;<volume>26</volume>(<issue>145</issue>). <pub-id pub-id-type="doi">10.1183/16000617.0051-2017</pub-id> .<?supplied-pmid 28877976?><pub-id pub-id-type="pmid">28877976</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>du Bois</surname><given-names>RM</given-names></name>, <name><surname>Weycker</surname><given-names>D</given-names></name>, <name><surname>Albera</surname><given-names>C</given-names></name>, <name><surname>Bradford</surname><given-names>WZ</given-names></name>, <name><surname>Costabel</surname><given-names>U</given-names></name>, <name><surname>Kartashov</surname><given-names>A</given-names></name>, <etal>et al</etal><article-title>Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis</article-title>. <source>American journal of respiratory and critical care medicine</source>. <year>2011</year>;<volume>184</volume>(<issue>4</issue>):<fpage>459</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201011-1790OC</pub-id> .<?supplied-pmid 21616999?><pub-id pub-id-type="pmid">21616999</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Collard</surname><given-names>HR</given-names></name>, <name><surname>King</surname><given-names>TE</given-names><suffix>Jr.</suffix></name>, <name><surname>Bartelson</surname><given-names>BB</given-names></name>, <name><surname>Vourlekis</surname><given-names>JS</given-names></name>, <name><surname>Schwarz</surname><given-names>MI</given-names></name>, <name><surname>Brown</surname><given-names>KK</given-names></name>. <article-title>Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis</article-title>. <source>American journal of respiratory and critical care medicine</source>. <year>2003</year>;<volume>168</volume>(<issue>5</issue>):<fpage>538</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.200211-1311OC</pub-id> .<?supplied-pmid 12773325?><pub-id pub-id-type="pmid">12773325</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Ley</surname><given-names>B</given-names></name>, <name><surname>Ryerson</surname><given-names>CJ</given-names></name>, <name><surname>Vittinghoff</surname><given-names>E</given-names></name>, <name><surname>Ryu</surname><given-names>JH</given-names></name>, <name><surname>Tomassetti</surname><given-names>S</given-names></name>, <name><surname>Lee</surname><given-names>JS</given-names></name>, <etal>et al</etal><article-title>A multidimensional index and staging system for idiopathic pulmonary fibrosis</article-title>. <source>Ann Intern Med</source>. <year>2012</year>;<volume>156</volume>(<issue>10</issue>):<fpage>684</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-156-10-201205150-00004</pub-id> .<?supplied-pmid 22586007?><pub-id pub-id-type="pmid">22586007</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>Kondoh</surname><given-names>S</given-names></name>, <name><surname>Chiba</surname><given-names>H</given-names></name>, <name><surname>Nishikiori</surname><given-names>H</given-names></name>, <name><surname>Umeda</surname><given-names>Y</given-names></name>, <name><surname>Kuronuma</surname><given-names>K</given-names></name>, <name><surname>Otsuka</surname><given-names>M</given-names></name>, <etal>et al</etal><article-title>Validation of the Japanese disease severity classification and the GAP model in Japanese patients with idiopathic pulmonary fibrosis</article-title>. <source>Respir Investig</source>. <year>2016</year>;<volume>54</volume>(<issue>5</issue>):<fpage>327</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.resinv.2016.02.009</pub-id> .<?supplied-pmid 27566380?><pub-id pub-id-type="pmid">27566380</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>SH</given-names></name>, <name><surname>Park</surname><given-names>JS</given-names></name>, <name><surname>Kim</surname><given-names>SY</given-names></name>, <name><surname>Kim</surname><given-names>DS</given-names></name>, <name><surname>Kim</surname><given-names>YW</given-names></name>, <name><surname>Chung</surname><given-names>MP</given-names></name>, <etal>et al</etal><article-title>Comparison of CPI and GAP models in patients with idiopathic pulmonary fibrosis: a nationwide cohort study</article-title>. <source>Sci Rep</source>. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>4784</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-23073-3</pub-id><?supplied-pmid 29555917?><pub-id pub-id-type="pmid">29555917</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref009">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Sharp</surname><given-names>C</given-names></name>, <name><surname>Adamali</surname><given-names>HI</given-names></name>, <name><surname>Millar</surname><given-names>AB</given-names></name>. <article-title>A comparison of published multidimensional indices to predict outcome in idiopathic pulmonary fibrosis</article-title>. <source>ERJ Open Res</source>. <year>2017</year>;<volume>3</volume>(<issue>1</issue>). <pub-id pub-id-type="doi">10.1183/23120541.00096-2016</pub-id><?supplied-pmid 28326312?><pub-id pub-id-type="pmid">28326312</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Silhan</surname><given-names>LL JC</given-names></name>, <name><surname>Shah</surname><given-names>PD</given-names></name>, <name><surname>Danoff</surname><given-names>SK</given-names></name>. <article-title>Comparison of the GAP Model and the Lung Allocation Score in Patients with Idiopathic Pulmonary Fibrosis/Interstitial Lung Disease Undergoing Lung Transplantation</article-title>. <source>J Pulm Med Respir Res</source>. <year>2016</year>;<volume>2</volume>:<fpage>007</fpage>.</mixed-citation>
              </ref>
              <ref id="pone.0221905.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Celli</surname><given-names>BR</given-names></name>, <name><surname>Cote</surname><given-names>CG</given-names></name>, <name><surname>Marin</surname><given-names>JM</given-names></name>, <name><surname>Casanova</surname><given-names>C</given-names></name>, <name><surname>Montes de Oca</surname><given-names>M</given-names></name>, <name><surname>Mendez</surname><given-names>RA</given-names></name>, <etal>et al</etal><article-title>The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease</article-title>. <source>N Engl J Med</source>. <year>2004</year>;<volume>350</volume>(<issue>10</issue>):<fpage>1005</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa021322</pub-id> .<?supplied-pmid 14999112?><pub-id pub-id-type="pmid">14999112</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>Prescott</surname><given-names>E</given-names></name>, <name><surname>Almdal</surname><given-names>T</given-names></name>, <name><surname>Mikkelsen</surname><given-names>KL</given-names></name>, <name><surname>Tofteng</surname><given-names>CL</given-names></name>, <name><surname>Vestbo</surname><given-names>J</given-names></name>, <name><surname>Lange</surname><given-names>P</given-names></name>. <article-title>Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study</article-title>. <source>Eur Respir J</source>. <year>2002</year>;<volume>20</volume>(<issue>3</issue>):<fpage>539</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.02.00532002</pub-id> .<?supplied-pmid 12358326?><pub-id pub-id-type="pmid">12358326</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Baker</surname><given-names>JF</given-names></name>, <name><surname>Billig</surname><given-names>E</given-names></name>, <name><surname>Michaud</surname><given-names>K</given-names></name>, <name><surname>Ibrahim</surname><given-names>S</given-names></name>, <name><surname>Caplan</surname><given-names>L</given-names></name>, <name><surname>Cannon</surname><given-names>GW</given-names></name>, <etal>et al</etal><article-title>Weight Loss, the Obesity Paradox, and the Risk of Death in Rheumatoid Arthritis</article-title>. <source>Arthritis Rheumatol</source>. <year>2015</year>;<volume>67</volume>(<issue>7</issue>):<fpage>1711</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1002/art.39136</pub-id>
<?supplied-pmid 25940140?><pub-id pub-id-type="pmid">25940140</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Fonarow</surname><given-names>GC</given-names></name>, <name><surname>Srikanthan</surname><given-names>P</given-names></name>, <name><surname>Costanzo</surname><given-names>MR</given-names></name>, <name><surname>Cintron</surname><given-names>GB</given-names></name>, <name><surname>Lopatin</surname><given-names>M</given-names></name>, <name><surname>Committee</surname><given-names>ASA</given-names></name>, <etal>et al</etal><article-title>An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry</article-title>. <source>Am Heart J</source>. <year>2007</year>;<volume>153</volume>(<issue>1</issue>):<fpage>74</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.ahj.2006.09.007</pub-id> .<?supplied-pmid 17174642?><pub-id pub-id-type="pmid">17174642</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref015">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>Alakhras</surname><given-names>M</given-names></name>, <name><surname>Decker</surname><given-names>PA</given-names></name>, <name><surname>Nadrous</surname><given-names>HF</given-names></name>, <name><surname>Collazo-Clavell</surname><given-names>M</given-names></name>, <name><surname>Ryu</surname><given-names>JH</given-names></name>. <article-title>Body mass index and mortality in patients with idiopathic pulmonary fibrosis</article-title>. <source>Chest</source>. <year>2007</year>;<volume>131</volume>(<issue>5</issue>):<fpage>1448</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1378/chest.06-2784</pub-id> .<?supplied-pmid 17400656?><pub-id pub-id-type="pmid">17400656</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Kishaba</surname><given-names>T</given-names></name>, <name><surname>Nagano</surname><given-names>H</given-names></name>, <name><surname>Nei</surname><given-names>Y</given-names></name>, <name><surname>Yamashiro</surname><given-names>S</given-names></name>. <article-title>Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients</article-title>. <source>J Thorac Dis</source>. <year>2016</year>;<volume>8</volume>(<issue>12</issue>):<fpage>3596</fpage>–<lpage>604</lpage>. <pub-id pub-id-type="doi">10.21037/jtd.2016.12.49</pub-id>
<?supplied-pmid 28149554?><pub-id pub-id-type="pmid">28149554</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref017">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>Nakatsuka</surname><given-names>Y</given-names></name>, <name><surname>Handa</surname><given-names>T</given-names></name>, <name><surname>Kokosi</surname><given-names>M</given-names></name>, <name><surname>Tanizawa</surname><given-names>K</given-names></name>, <name><surname>Puglisi</surname><given-names>S</given-names></name>, <name><surname>Jacob</surname><given-names>J</given-names></name>, <etal>et al</etal><article-title>The Clinical Significance of Body Weight Loss in Idiopathic Pulmonary Fibrosis Patients</article-title>. <source>Respiration</source>. <year>2018</year>;<volume>96</volume>(<issue>4</issue>):<fpage>338</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1159/000490355</pub-id> .<?supplied-pmid 30130749?><pub-id pub-id-type="pmid">30130749</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref018">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>Pugashetti</surname><given-names>J</given-names></name>, <name><surname>Graham</surname><given-names>J</given-names></name>, <name><surname>Boctor</surname><given-names>N</given-names></name>, <name><surname>Mendez</surname><given-names>C</given-names></name>, <name><surname>Foster</surname><given-names>E</given-names></name>, <name><surname>Juarez</surname><given-names>M</given-names></name>, <etal>et al</etal><article-title>Weight loss as a predictor of mortality in patients with interstitial lung disease</article-title>. <source>Eur Respir J</source>. <year>2018</year>;<volume>52</volume>(<issue>3</issue>). <pub-id pub-id-type="doi">10.1183/13993003.01289-2018</pub-id> .<?supplied-pmid 30072505?><pub-id pub-id-type="pmid">30072505</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref019">
                <label>19</label>
                <mixed-citation publication-type="journal"><name><surname>Balasubramanian</surname><given-names>VP</given-names></name>, <name><surname>Varkey</surname><given-names>B</given-names></name>. <article-title>Chronic obstructive pulmonary disease: effects beyond the lungs</article-title>. <source>Curr Opin Pulm Med</source>. <year>2006</year>;<volume>12</volume>(<issue>2</issue>):<fpage>106</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1097/01.mcp.0000208449.73101.ac</pub-id> .<?supplied-pmid 16456379?><pub-id pub-id-type="pmid">16456379</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>Konishi</surname><given-names>M</given-names></name>, <name><surname>Ebner</surname><given-names>N</given-names></name>, <name><surname>von Haehling</surname><given-names>S</given-names></name>, <name><surname>Anker</surname><given-names>SD</given-names></name>, <name><surname>Springer</surname><given-names>J</given-names></name>. <article-title>Developing models for cachexia and their implications in drug discovery</article-title>. <source>Expert Opin Drug Discov</source>. <year>2015</year>;<volume>10</volume>(<issue>7</issue>):<fpage>743</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1517/17460441.2015.1041914</pub-id> .<?supplied-pmid 25927848?><pub-id pub-id-type="pmid">25927848</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref021">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>Sanders</surname><given-names>KJ</given-names></name>, <name><surname>Kneppers</surname><given-names>AE</given-names></name>, <name><surname>van de Bool</surname><given-names>C</given-names></name>, <name><surname>Langen</surname><given-names>RC</given-names></name>, <name><surname>Schols</surname><given-names>AM</given-names></name>. <article-title>Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective</article-title>. <source>J Cachexia Sarcopenia Muscle</source>. <year>2016</year>;<volume>7</volume>(<issue>1</issue>):<fpage>5</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1002/jcsm.12062</pub-id>
<?supplied-pmid 27066314?><pub-id pub-id-type="pmid">27066314</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref022">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Brusasco</surname><given-names>V</given-names></name>, <name><surname>Crapo</surname><given-names>R</given-names></name>, <name><surname>Viegi</surname><given-names>G</given-names></name>, <name><surname>American Thoracic</surname><given-names>S</given-names></name>, <name><surname>European Respiratory</surname><given-names>S</given-names></name>. <article-title>Coming together: the ATS/ERS consensus on clinical pulmonary function testing</article-title>. <source>Eur Respir J</source>. <year>2005</year>;<volume>26</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.05.00034205</pub-id> .<?supplied-pmid 15994380?><pub-id pub-id-type="pmid">15994380</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Gilani</surname><given-names>SR</given-names></name>, <name><surname>Vuga</surname><given-names>LJ</given-names></name>, <name><surname>Lindell</surname><given-names>KO</given-names></name>, <name><surname>Gibson</surname><given-names>KF</given-names></name>, <name><surname>Xue</surname><given-names>J</given-names></name>, <name><surname>Kaminski</surname><given-names>N</given-names></name>, <etal>et al</etal><article-title>CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis</article-title>. <source>PLoS One</source>. <year>2010</year>;<volume>5</volume>(<issue>1</issue>):<fpage>e8959</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0008959</pub-id><?supplied-pmid 20126467?><pub-id pub-id-type="pmid">20126467</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref024">
                <label>24</label>
                <mixed-citation publication-type="journal"><name><surname>Studer</surname><given-names>SM</given-names></name>, <name><surname>George</surname><given-names>MP</given-names></name>, <name><surname>Zhu</surname><given-names>X</given-names></name>, <name><surname>Song</surname><given-names>Y</given-names></name>, <name><surname>Valentine</surname><given-names>VG</given-names></name>, <name><surname>Stoner</surname><given-names>MW</given-names></name>, <etal>et al</etal><article-title>CD28 down-regulation on CD4 T cells is a marker for graft dysfunction in lung transplant recipients</article-title>. <source>American journal of respiratory and critical care medicine</source>. <year>2008</year>;<volume>178</volume>(<issue>7</issue>):<fpage>765</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.200701-013OC</pub-id>
<?supplied-pmid 18617642?><pub-id pub-id-type="pmid">18617642</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref025">
                <label>25</label>
                <mixed-citation publication-type="journal"><name><surname>Paterniti</surname><given-names>MO</given-names></name>, <name><surname>Bi</surname><given-names>Y</given-names></name>, <name><surname>Rekic</surname><given-names>D</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Karimi-Shah</surname><given-names>BA</given-names></name>, <name><surname>Chowdhury</surname><given-names>BA</given-names></name>. <article-title>Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis</article-title>. <source>Ann Am Thorac Soc</source>. <year>2017</year>;<volume>14</volume>(<issue>9</issue>):<fpage>1395</fpage>–<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1513/AnnalsATS.201606-458OC</pub-id> .<?supplied-pmid 28388260?><pub-id pub-id-type="pmid">28388260</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref026">
                <label>26</label>
                <mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Pleasants</surname><given-names>RA</given-names></name>, <name><surname>Croft</surname><given-names>JB</given-names></name>, <name><surname>Lugogo</surname><given-names>N</given-names></name>, <name><surname>Ohar</surname><given-names>J</given-names></name>, <name><surname>Heidari</surname><given-names>K</given-names></name>, <etal>et al</etal><article-title>Body mass index, respiratory conditions, asthma, and chronic obstructive pulmonary disease</article-title>. <source>Respir Med</source>. <year>2015</year>;<volume>109</volume>(<issue>7</issue>):<fpage>851</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.rmed.2015.05.006</pub-id>
<?supplied-pmid 26006753?><pub-id pub-id-type="pmid">26006753</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref027">
                <label>27</label>
                <mixed-citation publication-type="journal"><name><surname>Onen</surname><given-names>ZP</given-names></name>, <name><surname>Gulbay</surname><given-names>BE</given-names></name>, <name><surname>Sen</surname><given-names>E</given-names></name>, <name><surname>Yildiz</surname><given-names>OA</given-names></name>, <name><surname>Saryal</surname><given-names>S</given-names></name>, <name><surname>Acican</surname><given-names>T</given-names></name>, <etal>et al</etal><article-title>Analysis of the factors related to mortality in patients with bronchiectasis</article-title>. <source>Respir Med</source>. <year>2007</year>;<volume>101</volume>(<issue>7</issue>):<fpage>1390</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.rmed.2007.02.002</pub-id> .<?supplied-pmid 17374480?><pub-id pub-id-type="pmid">17374480</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref028">
                <label>28</label>
                <mixed-citation publication-type="journal"><name><surname>Dumitriu</surname><given-names>IE</given-names></name>. <article-title>The life (and death) of CD4+ CD28(null) T cells in inflammatory diseases</article-title>. <source>Immunology</source>. <year>2015</year>;<volume>146</volume>(<issue>2</issue>):<fpage>185</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1111/imm.12506</pub-id>
<?supplied-pmid 26190355?><pub-id pub-id-type="pmid">26190355</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref029">
                <label>29</label>
                <mixed-citation publication-type="journal"><name><surname>Bonham C</surname><given-names>HC</given-names></name>, <name><surname>Manns</surname><given-names>S</given-names></name>, <name><surname>Adegunsoye</surname><given-names>A</given-names></name>, <name><surname>Blaine</surname><given-names>K</given-names></name>, <name><surname>Jaffery</surname><given-names>R</given-names></name>, <name><surname>Vij</surname><given-names>MM</given-names></name>, <name><surname>Churpek</surname><given-names>ME</given-names></name>, <name><surname>Strek</surname><given-names>I</given-names></name>, <name><surname>Sperling</surname><given-names>AI</given-names></name>. <article-title>Stratification of idiopathic pulmoary fibrosis by ICOS and CD28 surface expression on T cells</article-title>. <source>American Thoracic Society</source><year>2017</year>.</mixed-citation>
              </ref>
              <ref id="pone.0221905.ref030">
                <label>30</label>
                <mixed-citation publication-type="journal"><name><surname>Feghali-Bostwick</surname><given-names>CA</given-names></name>, <name><surname>Tsai</surname><given-names>CG</given-names></name>, <name><surname>Valentine</surname><given-names>VG</given-names></name>, <name><surname>Kantrow</surname><given-names>S</given-names></name>, <name><surname>Stoner</surname><given-names>MW</given-names></name>, <name><surname>Pilewski</surname><given-names>JM</given-names></name>, <etal>et al</etal><article-title>Cellular and humoral autoreactivity in idiopathic pulmonary fibrosis</article-title>. <source>J Immunol</source>. <year>2007</year>;<volume>179</volume>(<issue>4</issue>):<fpage>2592</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.179.4.2592</pub-id> .<?supplied-pmid 17675522?><pub-id pub-id-type="pmid">17675522</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref031">
                <label>31</label>
                <mixed-citation publication-type="journal"><name><surname>Herazo-Maya</surname><given-names>JD</given-names></name>, <name><surname>Noth</surname><given-names>I</given-names></name>, <name><surname>Duncan</surname><given-names>SR</given-names></name>, <name><surname>Kim</surname><given-names>S</given-names></name>, <name><surname>Ma</surname><given-names>SF</given-names></name>, <name><surname>Tseng</surname><given-names>GC</given-names></name>, <etal>et al</etal><article-title>Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis</article-title>. <source>Sci Transl Med</source>. <year>2013</year>;<volume>5</volume>(<issue>205</issue>):205ra136. <pub-id pub-id-type="doi">10.1126/scitranslmed.3005964</pub-id><?supplied-pmid 24089408?><pub-id pub-id-type="pmid">24089408</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref032">
                <label>32</label>
                <mixed-citation publication-type="journal"><name><surname>Kahloon</surname><given-names>RA</given-names></name>, <name><surname>Xue</surname><given-names>J</given-names></name>, <name><surname>Bhargava</surname><given-names>A</given-names></name>, <name><surname>Csizmadia</surname><given-names>E</given-names></name>, <name><surname>Otterbein</surname><given-names>L</given-names></name>, <name><surname>Kass</surname><given-names>DJ</given-names></name>, <etal>et al</etal><article-title>Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses</article-title>. <source>American journal of respiratory and critical care medicine</source>. <year>2013</year>;<volume>187</volume>(<issue>7</issue>):<fpage>768</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201203-0506OC</pub-id>
<?supplied-pmid 23262513?><pub-id pub-id-type="pmid">23262513</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref033">
                <label>33</label>
                <mixed-citation publication-type="journal"><name><surname>Kotsianidis</surname><given-names>I</given-names></name>, <name><surname>Nakou</surname><given-names>E</given-names></name>, <name><surname>Bouchliou</surname><given-names>I</given-names></name>, <name><surname>Tzouvelekis</surname><given-names>A</given-names></name>, <name><surname>Spanoudakis</surname><given-names>E</given-names></name>, <name><surname>Steiropoulos</surname><given-names>P</given-names></name>, <etal>et al</etal><article-title>Global impairment of CD4+CD25+FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis</article-title>. <source>American journal of respiratory and critical care medicine</source>. <year>2009</year>;<volume>179</volume>(<issue>12</issue>):<fpage>1121</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.200812-1936OC</pub-id> .<?supplied-pmid 19342412?><pub-id pub-id-type="pmid">19342412</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref034">
                <label>34</label>
                <mixed-citation publication-type="journal"><name><surname>Vuga</surname><given-names>LJ</given-names></name>, <name><surname>Tedrow</surname><given-names>JR</given-names></name>, <name><surname>Pandit</surname><given-names>KV</given-names></name>, <name><surname>Tan</surname><given-names>J</given-names></name>, <name><surname>Kass</surname><given-names>DJ</given-names></name>, <name><surname>Xue</surname><given-names>J</given-names></name>, <etal>et al</etal><article-title>C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis</article-title>. <source>American journal of respiratory and critical care medicine</source>. <year>2014</year>;<volume>189</volume>(<issue>8</issue>):<fpage>966</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201309-1592OC</pub-id>
<?supplied-pmid 24628285?><pub-id pub-id-type="pmid">24628285</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref035">
                <label>35</label>
                <mixed-citation publication-type="journal"><name><surname>Xue</surname><given-names>J</given-names></name>, <name><surname>Kass</surname><given-names>DJ</given-names></name>, <name><surname>Bon</surname><given-names>J</given-names></name>, <name><surname>Vuga</surname><given-names>L</given-names></name>, <name><surname>Tan</surname><given-names>J</given-names></name>, <name><surname>Csizmadia</surname><given-names>E</given-names></name>, <etal>et al</etal><article-title>Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients</article-title>. <source>J Immunol</source>. <year>2013</year>;<volume>191</volume>(<issue>5</issue>):<fpage>2089</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1203476</pub-id>
<?supplied-pmid 23872052?><pub-id pub-id-type="pmid">23872052</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref036">
                <label>36</label>
                <mixed-citation publication-type="journal"><name><surname>Friedman</surname><given-names>JM</given-names></name>, <name><surname>Halaas</surname><given-names>JL</given-names></name>. <article-title>Leptin and the regulation of body weight in mammals</article-title>. <source>Nature</source>. <year>1998</year>;<volume>395</volume>(<issue>6704</issue>):<fpage>763</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1038/27376</pub-id> .<?supplied-pmid 9796811?><pub-id pub-id-type="pmid">9796811</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref037">
                <label>37</label>
                <mixed-citation publication-type="journal"><name><surname>Neumann</surname><given-names>E</given-names></name>, <name><surname>Lepper</surname><given-names>N</given-names></name>, <name><surname>Vasile</surname><given-names>M</given-names></name>, <name><surname>Riccieri</surname><given-names>V</given-names></name>, <name><surname>Peters</surname><given-names>M</given-names></name>, <name><surname>Meier</surname><given-names>F</given-names></name>, <etal>et al</etal><article-title>Adipokine expression in systemic sclerosis lung and gastrointestinal organ involvement</article-title>. <source>Cytokine</source>. <year>2019</year>;<volume>117</volume>:<fpage>41</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.cyto.2018.11.013</pub-id> .<?supplied-pmid 30784899?><pub-id pub-id-type="pmid">30784899</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref038">
                <label>38</label>
                <mixed-citation publication-type="journal"><name><surname>Oh</surname><given-names>YM</given-names></name>, <name><surname>Jeong</surname><given-names>BH</given-names></name>, <name><surname>Woo</surname><given-names>SY</given-names></name>, <name><surname>Kim</surname><given-names>SY</given-names></name>, <name><surname>Kim</surname><given-names>H</given-names></name>, <name><surname>Lee</surname><given-names>JH</given-names></name>, <etal>et al</etal><article-title>Association of plasma adipokines with chronic obstructive pulmonary disease severity and progression</article-title>. <source>Ann Am Thorac Soc</source>. <year>2015</year>;<volume>12</volume>(<issue>7</issue>):<fpage>1005</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1513/AnnalsATS.201501-005OC</pub-id> .<?supplied-pmid 26010877?><pub-id pub-id-type="pmid">26010877</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref039">
                <label>39</label>
                <mixed-citation publication-type="journal"><name><surname>Vernooy</surname><given-names>JH</given-names></name>, <name><surname>Drummen</surname><given-names>NE</given-names></name>, <name><surname>van Suylen</surname><given-names>RJ</given-names></name>, <name><surname>Cloots</surname><given-names>RH</given-names></name>, <name><surname>Moller</surname><given-names>GM</given-names></name>, <name><surname>Bracke</surname><given-names>KR</given-names></name>, <etal>et al</etal><article-title>Enhanced pulmonary leptin expression in patients with severe COPD and asymptomatic smokers</article-title>. <source>Thorax</source>. <year>2009</year>;<volume>64</volume>(<issue>1</issue>):<fpage>26</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1136/thx.2007.085423</pub-id> .<?supplied-pmid 18835960?><pub-id pub-id-type="pmid">18835960</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref040">
                <label>40</label>
                <mixed-citation publication-type="journal"><name><surname>La Cava</surname><given-names>A</given-names></name>, <name><surname>Matarese</surname><given-names>G</given-names></name>. <article-title>The weight of leptin in immunity</article-title>. <source>Nat Rev Immunol</source>. <year>2004</year>;<volume>4</volume>(<issue>5</issue>):<fpage>371</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nri1350</pub-id> .<?supplied-pmid 15122202?><pub-id pub-id-type="pmid">15122202</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref041">
                <label>41</label>
                <mixed-citation publication-type="journal"><name><surname>Iikuni</surname><given-names>N</given-names></name>, <name><surname>Lam</surname><given-names>QL</given-names></name>, <name><surname>Lu</surname><given-names>L</given-names></name>, <name><surname>Matarese</surname><given-names>G</given-names></name>, <name><surname>La Cava</surname><given-names>A</given-names></name>. <article-title>Leptin and Inflammation</article-title>. <source>Curr Immunol Rev</source>. <year>2008</year>;<volume>4</volume>(<issue>2</issue>):<fpage>70</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.2174/157339508784325046</pub-id>
<?supplied-pmid 20198122?><pub-id pub-id-type="pmid">20198122</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref042">
                <label>42</label>
                <mixed-citation publication-type="journal"><name><surname>Fantuzzi</surname><given-names>G</given-names></name>, <name><surname>Faggioni</surname><given-names>R</given-names></name>. <article-title>Leptin in the regulation of immunity, inflammation, and hematopoiesis</article-title>. <source>J Leukoc Biol</source>. <year>2000</year>;<volume>68</volume>(<issue>4</issue>):<fpage>437</fpage>–<lpage>46</lpage>. .<?supplied-pmid 11037963?><pub-id pub-id-type="pmid">11037963</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref043">
                <label>43</label>
                <mixed-citation publication-type="journal"><name><surname>Stofkova</surname><given-names>A</given-names></name>. <article-title>Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity</article-title>. <source>Endocr Regul</source>. <year>2009</year>;<volume>43</volume>(<issue>4</issue>):<fpage>157</fpage>–<lpage>68</lpage>. .<?supplied-pmid 19908934?><pub-id pub-id-type="pmid">19908934</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref044">
                <label>44</label>
                <mixed-citation publication-type="journal"><name><surname>Fantuzzi</surname><given-names>G</given-names></name>. <article-title>Adipose tissue, adipokines, and inflammation</article-title>. <source>J Allergy Clin Immunol</source>. <year>2005</year>;<volume>115</volume>(<issue>5</issue>):<fpage>911</fpage>–<lpage>9</lpage>; quiz 20. <pub-id pub-id-type="doi">10.1016/j.jaci.2005.02.023</pub-id> .<?supplied-pmid 15867843?><pub-id pub-id-type="pmid">15867843</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0221905.ref045">
                <label>45</label>
                <mixed-citation publication-type="journal"><name><surname>Galli</surname><given-names>JA</given-names></name>, <name><surname>Pandya</surname><given-names>A</given-names></name>, <name><surname>Vega-Olivo</surname><given-names>M</given-names></name>, <name><surname>Dass</surname><given-names>C</given-names></name>, <name><surname>Zhao</surname><given-names>H</given-names></name>, <name><surname>Criner</surname><given-names>GJ</given-names></name>. <article-title>Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions</article-title>. <source>Respirology</source>. <year>2017</year>;<volume>22</volume>(<issue>6</issue>):<fpage>1171</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/resp.13024</pub-id> .<?supplied-pmid 28317233?><pub-id pub-id-type="pmid">28317233</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
